We report the production and characterization of a human monoclonal antibody reactive against the major envelope glycoprotein of human T-cell leukemia virus type I (HTLV-I), a virus linked to the etiology of adult T-cell leukemia. We exposed lymph-node cells derived from a patient with adult T-cell leukemia to the Epstein-Barr virus in vitro and obtained a B-cell clone (designated 0.5a) by a limiting dilution technique. The secreted product of 0.5a is a monoclonal antibody (also designated 0.5a; that is IgG1 and has K light chains) that binds to the cell membrane of T-cells infected with HTLV-I and lyses them in the presence of complement. The antibody does not react with HTLV-I-negative T cells. In electroblot assays, the monoclonal antibody detects a 46-kDa glycoprotein in disrupted HTLV-I virions and a 34-kDa product following digestion ofthe viral protein with endoglycosidase F. These molecules have been reported to represent the HTLV-I env gene products. The antibody does not react with HTLV-II and HTLV-Il virions. Glycoproteins of 61 and 68 kDa, which are known to be encoded at least in part by the env gene of HTLV-I, are precipitated by the antibody from endogenously radiolabeled HETLV-I-infected HUT 102-B2 and MT-2 cells, respectively. These results suggest that this human monoclonal antibody reacts with an env-encoded glycoprotein of HTLV-I. By using a competition assay with a biotin-labeled 0.5a antibody, we observed that 15 out of 15 patients with adult T-cell leukemia had antibodies that block binding of the 0.5a antibody to HTLV-I virions. This suggests that the antigen detected by 0.5a antibody is a common epitope recognized in HTLV-I-infected individuals in vivo. This antibody, as well as the general strategy for making human monoclonal antibodies reactive against pathogenic retroviruses, may have diagnostic or therapeutic application.
The human T-cell leukemia (lymphotropic) viruses (HTLV) represent an extended family of T-cell tropic retroviruses with three known members (1) . HTLV type I (HTLV-I) has transforming activity in vitro and is etiologically linked to adult T-cell leukemia (ATL), a fulminant lymphoproliferative disorder first recognized as a clinical entity in Japan (2) . HTLV-I is now known to be endemic in several parts of the world. HTLV-II, another retrovirus with transforming capacity in vitro, was isolated from a patient with a T-cell variant of hairy cell leukemia (3) . HTLV-III (1, 4) , also called lymphadenopathy-associated virus (LAV) (5), unlike HTLV-I and HTLV-II, does not appear to have a transforming activity in vitro. Rather, HTLV-III is lytic for certain kinds of T cells and has been linked to the etiology of acquired immunodeficiency syndrome (AIDS).
Specific antibodies to both gag and env antigens ofHTLV-I have been detected in people who are exposed to the virus. Moreover, it has been possible to generate a number of murine monoclonal antibodies against the p19 and p24 gag proteins of HTLV-I. By contrast, the generation of monoclonal antibodies against env proteins has proven to be extremely difficult. A murine monoclonal antibody against the HTLV-I transmembrane protein (p2OE) has been reported (6) . However, to our knowledge, no monoclonal antibodies with reactivity against the major env glycoprotein (gp46) are currently available, and the absence of such monoclonal antibodies has limited the immunologic and biologic characterization of the env gene region and its products. In this report, we describe the generation and characterization of a human monoclonal antibody reactive against the major env component of HTLV-I. We also report that 15 out of 15 patients with ATL had antibodies that bind to the same epitope recognized by the monoclonal antibody.
MATERIALS AND METHODS Cells. HUT 102-B2 (7), (8) , and MJ-tumor (9) cells are long-term cultured human T-cell lines known to produce HTLV-I. HTLV-I-infected T-cell clones YTA1H (10) and STH4 (unpublished clone) and uninfected clone YTA1 were derived from a healthy donor AY. C3-44 (3) and H9/IIIB (4) are human T-cell lines infected with HTLV-II and HTLV-III, respectively. H9 (4), HUT 78 (11), MOLT-4, and CCRF-CEM are human T-cell lines known to be negative for HTLV-I. Daudi dilution technique. Growing clones were expanded and screened for HTLV-I-specific antibody production. ELISA. The supernatants of B-cell clones were screened by an ELISA detecting HTLV-I-specific antibodies by comparing the specific binding activity to HTLV-I-producing cells and HTLV-I-negative cells. These supernatants were also tested with plates coated with disrupted viruses. Detailed procedures have been described by Lando et al. (13) .
Viruses. Double banded and disrupted virus used as antigens were prepared as described by Lando et al. (13) . conditions on a preparative NaDodSO4/10% polyacrylamide slab gel (14) and transferred electrophoretically to a nitrocellulose sheet (15) . Strips (10 gg of protein per strip) cut from the sheet were reacted with various antibodies. Bound antibodies were visualized by incubation with '25I-labeled protein A followed by autoradiography. Disrupted HTLV-I was also treated with endoglycosidase F (endo F) (New England Nuclear) at an enzyme:viral protein ratio of 345 milliunits/,ug in 0.1 M sodium phosphate buffer (pH 6.1), 1% Nonidet P-40, 0.1% NaDodSO4, 1% 2-mercaptoethanol, and 25 mM EDTA for 6 hr at 37°C. The mixture was dialyzed extensively against 10 mM ammonium bicarbonate and lyophilized. As a control, virus was treated with the same buffer without endo F. These samples as well as untreated virus were electrophoresed, blotted, and reacted with the supernatant of 0.5a (100 ng of IgG per ml).
Radioimmunoprecipitation Analysis. MT-2 cells (2 x 107) in cysteine-free medium were exposed to 35S-labeled cysteine (100 ,uCi/ml; 1 Ci = 37 GBq; New England Nuclear) for 3 hr.
A soluble cell lysate was obtained by disruption with RIPA buffer (0.15 M NaCl, 0.05 M Tris HCl, pH 7.2, 1% Triton X-100, 1% sodium deoxycholate, and 0.1% NaDodSO4) and centrifuged for 1 hr at 100,000 x g. The lysate supernatant was adsorbed once with 10 Al of normal human control serum bound to protein A-Sepharose (protein A beads, Pharmacia) before portions were reacted with various antibodies preabsorbed with protein A beads. Immunoprecipitates were analyzed by NaDodSO4/PAGE (14) .
HUT 102-B2 cells (8 x 106) were pretreated for 2 hr in culture with or without 10 ,ug of tunicamycin per ml, transferred to cysteine-free medium, and exposed to 1.25 mCi of 35S-labeled cysteine per ml in the presence or absence of 10 ,ug of tunicamycin per ml for 4 hr. Portions of soluble cell lysates obtained from these samples were analyzed by NaDodSO4/PAGE as described above.
Competitive Binding Assay. Microtiter plates were coated with disrupted HTLV-I virion (1.25 ,g/ml). Aliquots (50 IlI) of serially diluted unconjugated 0.5a antibody or serum samples were added with 50 ,ul of 0.5a antibody (2 ,ug/ml), which was biotin-conjugated by the method of Jackson et al. (16) . The competition in binding of biotin-conjugated 0.Sa antibody with serum samples were detected by alkaline phosphatase-conjugated avidin (Sigma) and substrate. The amounts of competing antibody were calculated from a standard inhibition curve obtained with unconjugated 0.5a. Serum samples from patients with smoldering ATL were kindly provided by K. Takatsuki (Kumamoto, Japan). RESULTS Establishment of a B-Cell Clone (0.5a) That Produces HTLV-I Specific Antibody. We obtained 30 EBV-transformed B-cell clones from an ATL patient. One of these clones, designated 0.5a, (from a multiwell plate with 0.5 cells per well) produced an antibody (0.5a antibody) that bound specifically to HTLV-I-producing cells. This antibody also reacted with HTLV-I but not with HTLV-II and -III as tested by ELISA (data not shown). 0.5a grew with a doubling time of approximately 6 days during which time it secreted about 5 pug of antibody per ml at an initial cell concentration of 3 x 105/ml. 0.5a has been continuously cultured in complete medium and maintained a stable level of antibody production for over 12 months. Epstein-Barr virus nuclear antigen was detected in 0.5a. HTLV-I proviral DNA was not detected in 0.5a by Southern blotting hybridization. Recloning of 0.5a cells produced eight subclones, all secreting the 0.5a monoclonal antibody that is specific for HTLV-I-producing cells. We observed that the 0.5a antibody had complement-fixing and Staphylococcal protein A-binding properties.
Surface Binding Activity and Complement-Mediated Cytotoxicity of 0.5a Antibody. We then tested the binding activity of this antibody to the surface of living cells by fluorescence-activated cell sorter. Fig. 1 shows representative sorter profiles using four HTLV-I-producing cell lines and four HTLV-I-negative cell lines. The 0.5a antibody bound to the surface membrane of HTLV-I-producing cells but not to that of HTLV-I-negative cells. This reactivity occurred with 100% of the HTLV-I-producing cell populations. We then analyzed the complement-mediated cytolytic activity of 0.5a antibody by using a trypan blue dye exclusion test. As shown in Fig. 2 , 0.5a antibody lysed almost all HTLV-I-producing HUT 102-B2 cells at a concentration of 5
,pg/ml but did not lyse HTLV-I-negative MOLT-4 cells even at a concentration of 125 pAg/ml. Protein A-purified polyclonal IgG from the serum of an ATL patient also lysed HUT 102-B2 cells, but it did so less effectively. A summary of the surface binding activity and cytolytic activity of 0.5a antibody with a wide range ofcell lines is provided in Table 1 . The antibody failed to bind to and lyse a variety of HTLV-Inegative cell lines, HTLV-II-producing C344 cells, HTLV-III-producing H9 cells, normal peripheral T-cells, and cultured normal T-cell blasts (phytohemagglutinin-blast). A normal T-cell clone YTA1, which was negative for 0.5a reactivity, became positive after HTLV-I infection (YTA1H). The 0.5a antibody did not react with cryopreserved fresh leukemic T cells from ATL patients. However, following short-term culture, reactivity with 0.5a appeared, and those cultured leukemic T cells were lysed, while the antibody did not react with cultured normal T cells (Table 1) . Lack of HTLV-I gene expression in fresh leukemic T cells has been observed; however, viral expression may be induced under short-term culture conditions (8, 17) . These data indicate that the 0.5a human monoclonal antibody can bind to the antigen specifically expressed on the surface of HTLV-I producing cells and can lyse such cells in the presence of complement. 42-kDa molecule as a minor band (Fig. 3A, lane a) . The former has a pattern of migration similar to that reported for the HTLV-I major envelope protein gp46 (18) (19) (20) (21) . The latter is presumably a variant cleavage product of the env gene, or a partially glycosylated product. Serum from a patient with ATL also detected gp46 as a broader band (Fig. 3A, lane e) . Antibodies to HTLV-I gag proteins (22, 23) did not detect these molecules. We also analyzed disrupted HTLV-II and -III viruses with 0.5a antibody in the same electroblot assay and observed no reactivity (data not shown).
We then treated the virus with endo F and analyzed the antigen detected by 0.5a antibody in an electroblot (Fig. 3B) . The antibody reacted with 34-kDa and 38-kDa products after endo F treatment (Fig. 3B, lane c) Analysis of the Antigen Detected by O.Me Antibody by Immunoprecipitation. The antigen detected by 0.5a antibody was further examined by immunoprecipitation of metabolically radiolabeled cell lysates. Fig. 4 shows that the 0.5a antibody precipitated two known env gene-encoded products gp6l and gp68 from HUT 102 (Fig. 4B, lane b) and MT-2 cells (Fig. 4A, lane c HUT 102 cells were then metabolically radiolabeled in the presence of tunicamycin and immunoprecipitated (Fig. 4B , lanes e-h). Following tunicamycin treatment, HUT 102 cells were reported to yield 46-kDa and 40-kDa proteins that are the deglycosylated forms of gp6l (21) . As shown in Fig. 4B , 0.5a antibody precipitated the 46-kDa and 41-kDa deglycosylated species that are not gag related as can be seen their lack of reactivity with reference anti-gag antibodies. Similar results were obtained by immunoprecipitating the tunicamycin-treated MT-2 cell lysate (data not shown).
These results, taken together, indicate that the antigen precipitated by the 0.Sa antibody is a glycoprotein not related to the gag proteins but related to the env gene product of HTLV-I.
Presence ofAntibodies in ATL Patient Sera Competing in the Binding of 0.5a Antibody to HTLV-I. We asked if there are antibodies in other patient sera that share an epitope reactivity with 0.5a antibody. We conjugated the purified 0.5a antibody with biotin and developed a competitive ELISA assay. Fifteen serum samples from ATL patients and 8 normal serum samples were tested. As shown in Table 2 , 15 out of 15 patients with ATL had competing antibodies, suggesting the antigenic epitope detected by 0.5a antibody is a common epitope recognized in HTLV-I-infected individuals in vivo.
DISCUSSION
Several features of the 0.5a human monoclonal B-cell line and its secreted antibody might be of special interest from a research perspective. First, the 0.5a B-cell line has exhibited a stable pattern of growth and specific antibody secretion for more than 12 months. Second, the secreted human IgG product fixes complement and binds to Staphylococcal protein A. Finally, the O.5a antibody-producing line was derived from a patient with adult T-cell leukemia (ATL), and the determinant detected by the antibody would, therefore, represent a viral antigen that is recognized by humans in response to HTLV-I infection in vivo. These features make the 0.5a antibody an important reagent for studying the natural history and-biology of HTLV-I infections. It has been reported that viruses belonging to the HTLV-I family share some -common nucleotide sequences (24) and antigenic epitopes (1, 25) . However, the epitope that was recognized by 0.5a is apparently not one in common with the other members of the HTLV family. In this respect, O.5a antibody might be useful for differential diagnosis of HTLV-II and -III infection. The antibody could also conceivably have value in clinical interventions against diseases linked to HTLV-I infection. If viral envelope antigen were expressed on the surface of tumor stem cells at some point in the clinical course of ATL or its smoldering variants (26) , it might be possible to use the antibody in experimental regimens for the therapy of these diseases. By the same token, the antibody might have an experimental therapeutic role if it were possible to first induce the expression of viral envelope in tumor cells by a pharmacologic or biologic agent in vivo. It is also possible that this human monoclonal antibody could facilitate an anti-HTLV-I vaccination process; anti-idiotypic antibodies to 0.5a antibody might be used as antigen substitutes to generate immunity without the use of virus or its products as antigens per se (27, 28) . We have produced a murine monoclonal antiidiotypic antibody against 0.5a antibody and our preliminary results indicate that this antiidiotypic antibody can be used to raise antibodies to HTLV-I following injection into a rabbit (unpublished results).
